** Analysts at Citi believe Nanosonics NAN.AX remains
vulnerable to potential for increased competition as a
one-product company
** Broker maintains A$3.90/shr target price; maintains
"sell" rating
** Citi also sees risk for the infection prevention services
provider being vulnerable to newer technology that could make
their only product obsolete
** Should the impact of these factors be greater than
expected, the stock may have difficulty in achieving our
earnings estimates and valuation - Citi
** Three of eleven analysts rate stock "buy" or higher, five
rate "hold" and three rate "sell" or lower; their median PT is
A$4.73 - LSEG data
** Stock down 0.7% YTD, as of last close
(Reporting by Shivangi Lahiri in Bengaluru)
((shivangi.lahiri@thomsonreuters.com))